RapaLink-1

Overview

RapaLink-1, the third-generation bivalent mTOR inhibitor, combines Rapamycin ( HY-10219 ) with MLN0128 (HY-13328, a second-generation mTOR kinase inhibitor) by an inert chemical linker. RapaLink-1 shows better efficacy than Rapamycin or mTOR kinase inhibitors (TORKi), potently blocking cancer-derived, activating mutants of mTOR . RapaLink-1 can cross the blood-brain barrier. RapaLink-1 binding to FKBP12 results in targeted and durable inhibition of mTORC1 . RapaLink-1 plays an antithrombotic role in antiphospholipid syndrome by improving autophagy . Anticancer activity.

Application

Products | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Signaling Pathways > Autophagy | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > mTOR | Products > Signaling Pathways > Autophagy

Product Information

• Catalog No.: HY-111373
• CAS No.: 1887095-82-0
• Molecular Formula: C91H138N12O24
• Molecular Weight: 1784.14
• Purity: 99.65%
• Storage: -20°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
• Solubility: ≥ 5 mg/mL (2.80 mM); Clear solution
• Availability: In-stock

Source

Original product source